Elicitation of health state utilities in neuroendocrine tumours

Abstract

Although vignette studies have been criticised for the difficulty in establishing their validity, the collection of health utilities in rare populations is challenging. The findings from this study suggest that advanced NETs is associated with a considerable HRQoL burden, both as a direct result of the disease and the potential of experiencing a number of severe adverse events. These values could assist in future economic evaluation processes.

Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial)

“…It has been previously reported that patients with NETs have worse HRQoL compared with the general population [18], and that treatment-related AEs are one of the factors contributing to poorer HRQoL [10]. For this reason, understanding the impact of therapies on patients’ HRQoL (in addition to disease status and tumor burden) is of considerable importance and of particular relevance for everolimus, given the known potential for toxicity.…”

“…Although survival rates have improved for patients with metastatic PanNENs, advanced NENs in general are still associated with a substantial health-related quality of life (HRQoL) burden, resulting from both the disease itself and treatment-related adverse events (AEs) [10]. Despite this, there is a paucity of HRQoL studies [11, 12], and the translation of HRQoL findings into clinical practice is hampered by the use of multiple HRQoL assessment tools, the use of only generic HRQoL tools in some studies, and a lack of comparative data between treatments [12].…”

Cost-Effectiveness of Pazopanib Compared with Sunitinib in Metastatic Renal Cell Carcinoma in Canada

“…Where the studies from Shabaruddin did not report specific aes, did not include utilities for a referent state from which the incremental effect of the ae on utilities could be calculated, included only Asian patients, or focused only on chemotherapy-induced nausea and vomiting, and where estimates from the Swinburn mrcc study 20 were already available, the Shabaruddin studies were not included. A total of fifteen studies, including the study by Swinburn, were identified 20,[22][23][24][25][26][27][28][29][30][31][32][33][34] .…”

Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion

“…For grade III/IV AEs: l diarrhoea taken directly from the SCOT trial 201 univariate estimates l nausea/vomiting taken as the mean of the SCOT trial 201 univariate estimates l hand and foot syndrome assumed to be greater than the diarrhoea decrement by the Best et al 190 proportion l mucositis taken from the SCOT trial 201 univariate estimates l neutropenia taken from the SCOT trial 201 univariate estimates l leucopenia assumed to be as per neutropenia l thrombocytopenia taken from Swinburn et al 200 However, in the light of expert opinion neutropenia, leucopenia and thrombocytopenia are assumed to have no QoL impact for the base case. Table 49 includes QoL decrements for the grade I/II AEs.…”

“…Swinburn et al 200 (funded by Novartis) used TTO among 100 members of the UK general public to estimate QoL values for health states associated with neuroendocrine tumours. Health state vignettes were developed based on the literature, clinician and patient interviews and five pilot interviews to check the appropriateness of the descriptions.…”